Novel Antischizophrenia Treatments

Mark A. Geyer, Gerhard Gross (Herausgeber)

Buch | Softcover

X, 458 Seiten

2014 | 2012
Springer Berlin (Verlag)
978-3-642-43809-7 (ISBN)

Artikel merken

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia.

From the reviews:

"The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective." (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

Erscheint lt. Verlag	9.11.2014
Reihe/Serie	Handbook of Experimental Pharmacology
Zusatzinfo	X, 458 p.
Verlagsort	Berlin
Sprache	englisch
Maße	155 x 235 mm
Gewicht	712 g
Themenwelt	Geisteswissenschaften ► Psychologie ► Biopsychologie / Neurowissenschaften
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie
	Medizin / Pharmazie ► Pharmazie ► PTA / PKA
Schlagworte	Cognition • neurotransmitters • Psychopharmacology • Schizophrenia
ISBN-10	3-642-43809-1 / 3642438091
ISBN-13	978-3-642-43809-7 / 9783642438097
Zustand	Neuware